Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY24 results · Oct–Dec 2023
Suven Life Sciences reported revenue from operations of ₹2.45 crore (down 18.4% from Q3 FY23) and net loss of ₹41.76 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.45 | 3.00 | −18.4% | 3.06 | −19.9% |
| Other income | 6.07 | 2.20 | +175.1% | 5.14 | +18.0% |
| Total income | 8.52 | 5.21 | +63.5% | 8.20 | +3.8% |
| Profit before tax | (41.76) | (51.12) | Loss narrowed | (12.68) | Loss widened |
| Net profit for the period | (41.76) | (51.12) | Loss narrowed | (12.68) | Loss widened |
| EPS, basic (₹) | (1.92) | (2.90) | Loss narrowed | (0.58) | Loss widened |
| Net margin (%) | -1704.1 | -1702.5 | -414.4 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.45 | 3.00 | −18.4% | 3.06 | −19.9% |
| Other income | 6.07 | 2.20 | +175.1% | 5.14 | +18.0% |
| Total income | 8.52 | 5.21 | +63.5% | 8.20 | +3.8% |
| Profit before tax | (4.77) | (6.63) | Loss narrowed | 2.75 | Turned loss |
| Net profit for the period | (4.77) | (6.63) | Loss narrowed | 2.75 | Turned loss |
| EPS, basic (₹) | (0.22) | (0.35) | Loss narrowed | 0.13 | Turned loss |
| Net margin (%) | -194.6 | -220.9 | 90.0 |
Consolidated
- Filed with BSE
- 07 Feb 2024, 12:17 IST
- Board meeting
- 30 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2024, 12:17 IST
- Board meeting
- 30 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE